Conditions: Diffuse Large B-cell Lymphoma Follicle Center Lymphoma
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 79
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the efficacy and safety of Zevalin compared with observation alone in participants who are in PET-negative complete remission after first-line R-CHOP or R-CHOP like therapy.

Detailed description:

Arms:
arm 1: Participants received rituximab 250 milligram per meter square (mg/m\^2) by intravenous infusion on Day 1. If required by the governing regulatory agency, rituximab was to be followed 4 hours later by In-111-Zevalin 5.0 millicurie (mCi) on Day 1. And on Days 7-9: participants received rituximab 250 mg/m\^2 by intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 millicurie/kilogram (mCi/kg) 10-minute intravenous push (0.3 mCi/kg in participants with a platelet count in 100,000/ microliter \[μL\] to 149,000/μL). arm 2: Participants who were randomized in this arm group did not receive any anti-lymphoma therapy unless they had a relapse of their disease.

Interventions: intervention 1: Zevalin intervention 2: Y-90-Zevalin intervention 3: Rituximab intervention 4: In-111 Zevalin
Intervention descriptions: intervention 1: Zevalin administered intravenous infusion. intervention 2: Y-90-Zevalin administered by intravenous infusion. intervention 3: Rituximab administered by intravenous infusion. intervention 4: In-111-Zevalin administered by intravenously.

Protocol document: